June 18, 2010 (UPDATED June 21, 2010) — The US Food and Drug Administration (FDA) has approved a single-capsule formulation of 0.5-mg dutasteride and 0.4-mg tamsulosin (Jalyn; GlaxoSmithKline) for ...

DUBLIN--(BUSINESS WIRE)--The "Dutasteride / Tamsulosin Sales, Price Analysis, & Sales Forecast - 2017" report has been added to ResearchAndMarkets.com's offering. Find out the sales of Dutasteride / ...

Symptoms of benign prostatic hyperplasia (BPH) affect approximately 50% of men aged 50 years or older, increasing to 90% of men aged 70 years and above. 1 The prevalence of lower urinary tract ...

Learn everything you need to know about Dutasteride And Tamsulosin-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, ...

This combination medication contains 5 alpha-reductase inhibitor and alpha-blocker, prescribed for benign prostatic hyperplasia (BPH).

Background The purpose of this study was to explore the budget impact of dutasteride plus tamsulosin fixed-dose combination (DUT + TAM FDC) versus tamsulosin monotherapy, in the treatment of patients ...

GlaxoSmithKline (GSK) announced today that the Swiss regulatory authority, Swissmedic, has granted approval for Duodart®, a fixed dose combination (FDC) of dutasteride (0.5mg) and tamsulosin (0.4mg).

Dutasteride (Avodart) treatment significantly reduces the relative risk of a prostate cancer (PCa) diagnosis in men with benign prostatic hyperplasia (BPH) undergoing screening with PSA tests and ...

Benign prostatic hyperplasia (BPH) is extremely common in the aging man and may cause significant lower urinary tract symptoms (LUTS) necessitating treatment. Drug treatment is the mainstay of ...

If you’ve been diagnosed with benign prostatic hyperplasia (BPH), your doctor may prescribe tamsulosin for you. BPH is also called enlarged prostate. It’s a noncancerous condition that affects adult ...